Search Results

You are looking at 181 - 183 of 183 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Edward E. Partridge, Nadeem R. Abu-Rustum, Susan M. Campos, Patrick J. Fahey, Michael Farmer, Rochelle L. Garcia, Anna Giuliano, Howard W. Jones III, Subodh M. Lele, Richard W. Lieberman, Stewart L. Massad, Mark A. Morgan, R. Kevin Reynolds, Helen E. Rhodes, Diljeet K. Singh, Karen Smith-McCune, Nelson Teng, Cornelia Liu Trimble, Fidel Valea, and Sharon Wilczynski

, tamoxifen therapy, anovulation, or hereditary nonpolyposis cancer syndrome (HNPCC). Patients aged 35 years or older and all those with atypical glandular endometrial cells, abnormal bleeding, or endometrial cancer risk factors should also undergo

Full access

Peter F. Coccia, Alberto S. Pappo, Lynda Beaupin, Virginia F. Borges, Scott C. Borinstein, Rashmi Chugh, Shira Dinner, Jeanelle Folbrecht, A. Lindsay Frazier, Robert Goldsby, Alexandra Gubin, Robert Hayashi, Mary S. Huang, Michael P. Link, John A. Livingston, Yousif Matloub, Frederick Millard, Kevin C. Oeffinger, Diane Puccetti, Damon Reed, Steven Robinson, Abby R. Rosenberg, Tara Sanft, Holly L. Spraker-Perlman, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Nicholas Yeager, Lisa A. Gurski, and Dorothy A. Shead

breast cancer, although for women treated with tamoxifen, a levonorgestrel-containing intrauterine system (IUS) may be preferable since it has been shown to reduce tamoxifen-induced endometrial changes without increasing the risk of breast cancer

Full access

. Eight patients were diagnosed with new liver, brain or lung metastasis within 18 to 24 months. Regarding hormone receptor status, 42% of patients had positive estrogen receptors. All of these patients were treated with tamoxifen. HER2/neu receptors were